Abstract:The transient receptor potential vanilloid type 1 (TRPV1), a non-selective cation channel, is known for its essential role in the pathogenesis of various pain conditions such as nerve damage induced hyperalgesia, diabetic neuropathy and cancer pain. Therefore, TRPV1 is considered as a promising target for the development of new anti-inflammatory and analgesic drugs. In the present study, a theoretical study on the functionalities of the molecular interactions between 236 active ligands and TRPV1 was carried out, using three-dimensional quantitative structure-activity relationships (3D-QSAR), molecular docking and molecular dynamics (MD) simulation approaches. The ligand-based CoMSIA model (obtained by use of a random division method for splitting the training and test sets) exhibits optimum predictivity (Q(2) = 0.522, R(ncv)(2) = 0.935, R(pred)(2) = 0.839). The results show that the models are useful tools for the prediction of the test sets as well as newly designed structures against TRPV1 activity. In addition, to verify the rationality of the random division method for splitting the dataset, we also used a self-organizing map (SOM) division approach for establishing the QSAR models. Interestingly, the obtained optimal CoMSIA model based on the SOM division exhibits almost the same proper statistical results (Q(2) = 0.521, R(ncv)(2) = 0.929, R(pred)(2) = 0.829) as the random division-derived model, proving the reasonability of both division methods for building the models. The contour plots of molecular fields along with docking and MD simulation have identified several key structural requirements responsible for the activity. The present work provides extremely useful guidelines for future structural modifications of this class of compounds towards the development of superior TRPV1 antagonists. The new computational insights presented in this study are expected to be valuable for the guideline and development of new potent TRPV1 antagonists.

Discovery of N -(1,4-Benzoxazin-3-one) urea analogs as Mode-Selective TRPV1 antagonists

Discovery of N -(1-(2-hydroxyethyl)quinolin-2-one)- N '-(1-phenyl-1H-pyrazol-5-yl)methyl) urea as Mode-Selective TRPV1 antagonist

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

A Set of Novel Capsaicin Analogs As Molecular Ruler for Conformational Change of the TRPV1 Ligand-Binding Pocket

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

Rational Design and Validation of a Vanilloid-Sensitive TRPV2 Ion Channel.

Activation of TRPV1 by Capsaicin Analogs with a Shorter or Longer Neck

Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists

<i>N</i>-(3-Acyloxy-2-benzylpropyl)-<i>N</i>‘-[4-(methylsulfonylamino)benzyl]thiourea Analogues: Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor

Analysis of Structure-Activity Relationships for the 'A-Region' of N-(4-T-Butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea Analogues As Trpv1 Antagonists

Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects in Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core.

Identification of novel selective TRPV3 antagonists based on virtual screening, molecular docking and bioassay

Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

N-[4-(Methylsulfonylamino)benzyl]thiourea Analogues As Vanilloid Receptor Antagonists: Analysis of Structure–activity Relationships for the ‘C-Region’

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

High Affinity Antagonists of the Vanilloid Receptor.

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.